Silverberg Bernstein Capital Management’s Pharming Group PHAR Stock Holding History

Silverberg Bernstein Capital Management’s Portfolio PHAR Stock Details PHAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$577K	Sell	41,547 -3,200	-7%	-$46.3K	0.22%	44
2026 Q1	$745K	Sell	44,747 -5,800	-11%	-$98.3K	0.41%	43
2025 Q4	$893K	Sell	50,547 -1,600	-3%	-$25.2K	0.52%	41
2025 Q3	$756K	Hold	52,147	–	–	0.46%	44
2025 Q2	$557K	Buy	52,147 +4,150	+9%	+$40.3K	0.38%	44
2025 Q1	$402K	Hold	47,997	–	–	0.37%	45
2024 Q4	$483K	Buy	47,997 +6,887	+17%	+$58.7K	0.43%	37
2024 Q3	$339K	Buy	41,110 +17,675	+75%	+$140K	0.31%	40
2024 Q2	$196K	Buy	23,435 +5,725	+32%	+$53.9K	0.19%	47
2024 Q1	$186K	Hold	17,710	–	–	0.18%	49
2023 Q4	$202K	Buy	+17,710	New	+$203K	0.19%	47

Other funds holding PHAR

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Silverberg Bernstein Capital Management's PHAR Position: Q2 2026 in Review

Silverberg Bernstein Capital Management reduced its Pharming Group (PHAR) stake by 7.2% in Q2 2026, selling an estimated $46.3K and leaving 41,547 shares worth $577K. The position accounts for 0.22% of the portfolio, ranked #44.

Silverberg Bernstein Capital Management first reported a position in PHAR in Q4 2023 and has held it in 11 quarters since. The position peaked at $893K in Q4 2025. 2 funds tracked by Wall St. Rank hold PHAR as of Q2 2026.

Silverberg Bernstein Capital Management held 41,547 shares of Pharming Group worth $577K as of Q2 2026.
Silverberg Bernstein Capital Management sold 3,200 Pharming Group shares in Q2 2026, an estimated $46.3K.
Pharming Group made up 0.22% of Silverberg Bernstein Capital Management's portfolio in Q2 2026, its #44 holding.
Silverberg Bernstein Capital Management first reported a position in Pharming Group in Q4 2023 and has held it in 11 quarters since.
Silverberg Bernstein Capital Management's Pharming Group position peaked at $893K in Q4 2025.
2 funds tracked by Wall St. Rank held Pharming Group as of Q2 2026.

Based on Silverberg Bernstein Capital Management's 13F filing for Q2 2026, filed 7 Jul 2026.